在淋巴结阴性,T1三阴性乳腺癌中辅助化疗
Jesus D Anampa1, Alvaro Alvarez Soto2, Rachel B Jimenez3
1Department of Medical Oncology, Montefiore Einstein Comprehensive Cancer Center, New York, New York, USA.
Cancer medicine
|November 4, 2025
概括
辅助化疗显著改善了早期三阴性乳腺癌 (TNBC) 患者的生存率. 生存益处在较大的T1c瘤中最为明显,突出显示化疗.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 临床试验 临床试验
背景情况:
- 辅助化疗对结节阴性,小三阴性乳腺癌 (TNBC) 的作用缺乏正式的临床试验数据.
- 这项研究评估了辅助化疗对这一特定患者群体的生存益处.
研究的目的:
- 在pT1N0M0 TNBC患者中评估辅助化疗对整体生存 (OS) 的益处.
- 分析不同瘤大小 (T1a,T1b,T1c) 和民族种族群体的生存差异.
主要方法:
- 从2010年至2019年对国家癌症数据库 (NCDB) 的回顾性分析.
- 包括pT1N0M0 TNBC的女性.
- 用于生存分析的卡普兰-梅尔和考克斯比例模型.
主要成果:
- 辅助化疗显著改善了pT1N0M0 TNBC患者的生存状况 (HR 0.51).
- 在所有瘤大小中观察到生存益处,在T1c瘤中5年生存益处最大 (93%对80%).
- 与非西班牙裔白人女性相比,非西班牙裔黑人女性的化疗生存益处较小.
结论:
- 辅助化疗与pT1N0M0 TNBC患者的生存率改善有关.
- 化疗的生存优势在T1c瘤中最大.
- 需要进一步的研究来确定用于个性化化疗选择的生物标志物.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K